IIL Partners with ICMR for India’s First Zika Vaccine

Summary: Indian Immunologicals Limited (IIL) has partnered with the Indian Council of Medical Research (ICMR) to develop India's first Zika virus vaccine, signing a Memorandum of Agreement to conduct phase I clinical trials. ICMR will fund these trials, which will take place at four sites across India. IIL is also collaborating with Griffith University in Australia and has completed pre-clinical tests for the vaccine. This initiative is part of IIL's broader efforts to create vaccines for various diseases, including Kyasanur Forest Disease and Chikungunya. The Zika virus, primarily spread by mosquitoes, currently lacks a licensed vaccine, making this development crucial for public health.